digital health startups weight loss glp-1 Riding the Wegovy wave: The shifting focus to GLP-1s to tap the $150bn drug market GLP-1 Weight-Loss Drugs Ride Health,
Description
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (surpass-3): A randomised, open-label, parallel-group, phase 3 trial
doi:10.1016/j.bmcl.2019.08.015
Polypharmacology: challenges and opportunities in drug discovery
7 After adjusting for age at diagnosis of IBD, sex, steroid use, prior ileus or intestinal obstruction, bowel surgery, diabetes, and type of IBD
